Boehringer Ingelheim canning 1,100 workers as it ditches plant

After years of FDA chidings and resultant drug shortages, Boehringer Ingelheim is pulling the plug on its Ben Venue contract manufacturing business by the end of the year, planning to lay off 1,100 workers. Article

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.